Joseph Loscalzo

List of Publications by Year
in descending order

258	27,520	8181 76	6131 159
papers	citations	h-index	g-index

263	263	263	35636
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The inclusion of augmented intelligence in medicine: A framework for successful implementation. Cell Reports Medicine, 2022, 3, 100485.	6.5	27
2	Comprehensive network medicine-based drug repositioning via integration of therapeutic efficacy and side effects. Npj Systems Biology and Applications, 2022, 8, 12.	3.0	9
3	The role of glutathione peroxidase-1 in health and disease. Free Radical Biology and Medicine, 2022, 188, 146-161.	2.9	61
4	What Causes Hypertrophic Cardiomyopathy?. American Journal of Cardiology, 2022, 179, 74-82.	1.6	10
5	Network medicine in Cardiovascular Research. Cardiovascular Research, 2021, 117, 2186-2202.	3.8	23
6	James T. Willerson, MD. Circulation, 2021, 143, 1537-1538.	1.6	0
7	An overview of the process, progress, and outcomes of a National Center for Accelerated Innovation: The Boston Biomedical Innovation Center Experience. Journal of Clinical and Translational Science, 2021, 5, e137.	0.6	0
8	Gene co-expression in the interactome: moving from correlation toward causation via an integrated approach to disease module discovery. Npj Systems Biology and Applications, 2021, 7, 3.	3.0	64
9	Associations of methyl donor and methylation inhibitor levels during anti-oxidant therapy in heart failure. Journal of Physiology and Biochemistry, 2021, 77, 295-304.	3.0	0
10	Comprehensive characterization of proteinâ€“protein interactions perturbed by disease mutations. Nature Genetics, 2021, 53, 342-353.	21.4	109
11	Temporal bias in case-control design: preventing reliable predictions of the future. Nature Communications, 2021, 12, 1107.	12.8	33
12	Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nature Communications, 2021, 12, 873.	12.8	53
13	Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside. Clinical Epigenetics, 2021, 13, 66.	4.1	36
14	A Treacherous Course. New England Journal of Medicine, 2021, 384, 860-865.	27.0	0
15	Network medicine framework shows that proximity of polyphenol targets and disease proteins predicts therapeutic effects of polyphenols. Nature Food, 2021, 2, 143-155.	14.0	57
16	NHLBI-CMREF Workshop Report on Pulmonary Vascular DiseaseÂClassification. Journal of the American College of Cardiology, 2021, 77, 2040-2052.	2.8	13
17	Superior Mesenteric Artery Dissection. JACC: Case Reports, 2021, 3, 690-693.	0.6	1
18	Immunometabolic Endothelial Phenotypes: Integrating Inflammation and Glucose Metabolism. Circulation Research, 2021, 129, 9-29.	4.5	38

#	Article	IF	Citations
19	Network medicine framework for identifying drug-repurposing opportunities for COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	245
20	COVID-19 and Cardiovascular Disease. Circulation Research, 2021, 128, 1214-1236.	4.5	232
21	Hypertensive Heartbreak. New England Journal of Medicine, 2021, 384, 2145-2152.	27.0	1
22	NEDD9 Is a Novel and Modifiable Mediator of Plateletâ€"Endothelial Adhesion in the Pulmonary Circulation. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1533-1545.	5.6	14
23	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circulation: Heart Failure, 2021, 14, .	3.9	11
24	Network moduleâ€based drug repositioning for pulmonary arterial hypertension. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 994-1005.	2.5	10
25	Retinal Protection by Sustained Nanoparticle Delivery of Oncostatin M and Ciliary Neurotrophic Factor Into Rodent Models of Retinal Degeneration. Translational Vision Science and Technology, 2021, 10, 6.	2.2	11
26	Selenium, a Micronutrient That Modulates Cardiovascular Health via Redox Enzymology. Nutrients, 2021, 13, 3238.	4.1	40
27	Interferon-Î³ Impairs Human Coronary Artery Endothelial Glucose Metabolism by Tryptophan Catabolism and Activates Fatty Acid Oxidation. Circulation, 2021, 144, 1612-1628.	1.6	36
28	Hard to Swallow. New England Journal of Medicine, 2021, 385, 1421-1427.	27.0	3
29	Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation. Basic Research in Cardiology, 2021, 116, 57.	5.9	3
30	A crosslinked dextran sulfate-chitosan nanoparticle for delivery of therapeutic heparin-binding proteins. International Journal of Pharmaceutics, 2021, 610, 121287.	5.2	3
31	Abstract 11024: Interferon-Gamma Impairs Human Coronary Artery Endothelial Glucose Metabolism via Tryptophan Catabolism and Activates Fatty Acid Oxidization. Circulation, 2021, 144, .	1.6	0
32	The Undiagnosed Diseases Network as a Tool for Graduate Medical Education. American Journal of Medicine, 2020, 133, e18-e22.	1.5	0
33	Metabolic Responses to Reductive Stress. Antioxidants and Redox Signaling, 2020, 32, 1330-1347.	5.4	211
34	The unmapped chemical complexity of our diet. Nature Food, 2020, 1, 33-37.	14.0	177
35	Systems biology and network medicine: An integrated approach to redox biology and pathobiology. , 2020, , 29-49.		2
36	Early-pregnancy transcriptome signatures of preeclampsia: from peripheral blood to placenta. Scientific Reports, 2020, 10, 17029.	3.3	10

#	Article	IF	Citations
37	Importance of scientific collaboration in contemporary drug discovery and development: a detailed network analysis. BMC Biology, 2020, 18, 138.	3.8	10
38	Strengthening national nutrition research: rationale and options for a new coordinated federal research effort and authority. American Journal of Clinical Nutrition, 2020, 112, 721-769.	4.7	35
39	A systematic comprehensive longitudinal evaluation of dietary factors associated with acute myocardial infarction and fatal coronary heart disease. Nature Communications, 2020, 11, 6074.	12.8	37
40	Robustness and lethality in multilayer biological molecular networks. Nature Communications, 2020, 11, 6043.	12.8	61
41	Network determinants of cardiovascular calcification and repositioned drug treatments. FASEB Journal, 2020, 34, 11087-11100.	0.5	19
42	A global network for network medicine. Npj Systems Biology and Applications, 2020, 6, 29.	3.0	19
43	The Game Is Afoot. New England Journal of Medicine, 2020, 382, 2249-2255.	27.0	1
44	MDH1-mediated malate-aspartate NADH shuttle maintains the activity levels of fetal liver hematopoietic stem cells. Blood, 2020, 136, 553-571.	1.4	13
45	Creating Real Change at Academic Medical Centers â€" How Social Movements Can Be Timely Catalysts. New England Journal of Medicine, 2020, 383, 199-201.	27.0	31
46	Response by Eberly et al to Letter Regarding Article, â€œIdentification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Centerâ€. Circulation: Heart Failure, 2020, 13, e007193.	3.9	3
47	Illuminating NAD+ Metabolism in Live Cells and InÂVivo Using a Genetically Encoded Fluorescent Sensor. Developmental Cell, 2020, 53, 240-252.e7.	7.0	71
48	Missing the Target. New England Journal of Medicine, 2020, 382, 1353-1359.	27.0	0
49	Target identification among known drugs by deep learning from heterogeneous networks. Chemical Science, 2020, 11, 1775-1797.	7.4	193
50	A Rapid Change in Pressure. New England Journal of Medicine, 2020, 382, 563-570.	27.0	4
51	The Network Medicine Imperative and the Need for an International Network Medicine Consortium. American Journal of Medicine, 2020, 133, e451-e454.	1.5	11
52	Molecular networks in Network Medicine: Development and applications. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2020, 12, e1489.	6.6	128
53	Parroting Lymphoma. New England Journal of Medicine, 2020, 383, 1376-1381.	27.0	1
54	The application of big data to cardiovascular disease: paths to precision medicine. Journal of Clinical Investigation, 2020, 130, 29-38.	8.2	74

#	Article	IF	Citations
55	Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19. ArXiv Org, 2020, , .	1.2	4
56	Network medicine and type 2 diabetes mellitus: insights into disease mechanism and guide to precision medicine. Endocrine, 2019, 66, 456-459.	2.3	7
57	Fine-Tuning of PGC1Î± Expression Regulates Cardiac Function and Longevity. Circulation Research, 2019, 125, 707-719.	4.5	47
58	A genome-wide positioning systems network algorithm for in silico drug repurposing. Nature Communications, 2019, 10, 3476.	12.8	134
59	Drugâ€Placebo Additivity in Randomized Clinical Trials. Clinical Pharmacology and Therapeutics, 2019, 106, 1191-1197.	4.7	11
60	Yield of whole exome sequencing in undiagnosed patients facing insurance coverage barriers to genetic testing. Journal of Genetic Counseling, 2019, 28, 1107-1118.	1.6	42
61	Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center. Circulation: Heart Failure, 2019, 12, e006214.	3.9	100
62	Systems pharmacogenomics â€“ gene, disease, drug and placebo interactions: a case study in COMT. Pharmacogenomics, 2019, 20, 529-551.	1.3	12
63	The Element of Surprise. New England Journal of Medicine, 2019, 381, 1365-1371.	27.0	4
64	A Disturbing Decline. New England Journal of Medicine, 2019, 380, 2257-2262.	27.0	2
65	Moving Beyond the Sarcomere to ExplainÂHeterogeneity in HypertrophicÂCardiomyopathy. Journal of the American College of Cardiology, 2019, 73, 1978-1986.	2.8	124
66	Network Medicine in Pathobiology. American Journal of Pathology, 2019, 189, 1311-1326.	3.8	55
67	Reported environmental exposures are inversely associated with obtaining a genetic diagnosis in the Undiagnosed Diseases Network. American Journal of Medical Genetics, Part A, 2019, 179, 958-965.	1.2	5
68	Gasping for a Diagnosis. New England Journal of Medicine, 2019, 380, 961-967.	27.0	0
69	Precision Medicine. Circulation Research, 2019, 124, 987-989.	4.5	18
70	A Dangerous Detour. New England Journal of Medicine, 2019, 380, 1360-1365.	27.0	1
71	Epigenetic Inheritance Underlying Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 653-664.	2.4	60
72	Reaction rate of pyruvate and hydrogen peroxide: assessing antioxidant capacity of pyruvate under biological conditions. Scientific Reports, 2019, 9, 19568.	3.3	47

#	Article	IF	Citations
73	Facing Uncertainty. New England Journal of Medicine, 2019, 381, 2253-2259.	27.0	3
74	Visualizing RNA dynamics in live cells with bright and stable fluorescent RNAs. Nature Biotechnology, 2019, 37, 1287-1293.	17.5	206
75	A Breath-Taking Diagnosis. New England Journal of Medicine, 2019, 380, 81-87.	27.0	3
76	An Unexpected Expectoration. New England Journal of Medicine, 2018, 378, 853-858.	27.0	0
77	A Systems Approach to Refine Disease Taxonomy by Integrating Phenotypic and Molecular Networks. EBioMedicine, 2018, 31, 79-91.	6.1	60
78	Pulmonary Comorbidity in Lung Cancer. Trends in Molecular Medicine, 2018, 24, 239-241.	6.7	8
79	Network Analysis to Risk Stratify Patients With Exercise Intolerance. Circulation Research, 2018, 122, 864-876.	4.5	42
80	Pre-clinical model of severe glutathione peroxidase-3 deficiency and chronic kidney disease results in coronary artery thrombosis and depressed left ventricular function. Nephrology Dialysis Transplantation, 2018, 33, 923-934.	0.7	30
81	Nitric Oxide Signaling and Atherothrombosis Redux. Circulation, 2018, 137, 233-236.	1.6	10
82	Emerging Role of Precision Medicine in Cardiovascular Disease. Circulation Research, 2018, 122, 1302-1315.	4.5	218
83	Case 8-2018: A 55-Year-Old Woman with Shock and Labile Blood Pressure. New England Journal of Medicine, 2018, 378, 1043-1053.	27.0	18
84	Spatiotemporal Multi-Omics Mapping Generates a Molecular Atlas of the Aortic Valve and Reveals Networks Driving Disease. Circulation, 2018, 138, 377-393.	1.6	180
85	Efficient Computational Modeling of Human Ventricular Activation and Its Electrocardiographic Representation: A Sensitivity Study. Cardiovascular Engineering and Technology, 2018, 9, 447-467.	1.6	5
86	NAD(H) and NADP(H) Redox Couples and Cellular Energy Metabolism. Antioxidants and Redox Signaling, 2018, 28, 251-272.	5.4	512
87	Determinants of drug-target interactions at the single cell level. PLoS Computational Biology, 2018, 14, e1006601.	3.2	23
88	Expert Panel Discusses the Importance of Systems Medicine. Systems Medicine (New Rochelle, N Y), 2018, 1, 3-8.	1.1	1
89	Analysis of redox landscapes and dynamics in living cells and in vivo using genetically encoded fluorescent sensors. Nature Protocols, 2018, 13, 2362-2386.	12.0	70
90	Effect of Genetic Diagnosis on Patients with Previously Undiagnosed Disease. New England Journal of Medicine, 2018, 379, 2131-2139.	27.0	261

#	Article	IF	Citations
91	Inflammation, Immunity, and Infection in Atherothrombosis. Journal of the American College of Cardiology, 2018, 72, 2071-2081.	2.8	389
92	MicroRNA Dysregulation in Pulmonary Arteries from Chronic Obstructive Pulmonary Disease. Relationships with Vascular Remodeling. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 490-499.	2.9	34
93	Network-Based Disease Module Discovery by a Novel Seed Connector Algorithm with Pathobiological Implications. Journal of Molecular Biology, 2018, 430, 2939-2950.	4.2	41
94	Case 8-2018: A Woman with Shock and Labile Blood Pressure. New England Journal of Medicine, 2018, 378, 2146-2147.	27.0	0
95	Controllability in an islet specific regulatory network identifies the transcriptional factor NFATC4, which regulates Type 2 Diabetes associated genes. Npj Systems Biology and Applications, 2018, 4, 25.	3.0	25
96	Dyspnea and Edema in a Woman With Antiphospholipid Syndrome. JAMA Cardiology, 2018, 3, 1123.	6.1	0
97	A Headache of a Diagnosis. New England Journal of Medicine, 2018, 379, 475-479.	27.0	5
98	Network-based approach to prediction and population-based validation of in silico drug repurposing. Nature Communications, 2018, 9, 2691.	12.8	351
99	An integrated clinical program and crowdsourcing strategy for genomic sequencing and Mendelian disease gene discovery. Npj Genomic Medicine, 2018, 3, 21.	3.8	24
100	A Shocking Turn of Events. New England Journal of Medicine, 2018, 378, 2225-2230.	27.0	2
101	NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension. Science Translational Medicine, 2018, 10, .	12.4	89
102	Making the Connection. New England Journal of Medicine, 2017, 376, 476-482.	27.0	2
103	International Exchange and American Medicine. New England Journal of Medicine, 2017, 376, e40.	27.0	13
104	The Undiagnosed Diseases Network: Accelerating Discovery about Health and Disease. American Journal of Human Genetics, 2017, 100, 185-192.	6.2	142
105	Precision Psychiatry Meets Network Medicine. JAMA Psychiatry, 2017, 74, 665.	11.0	19
106	Autoimmune Cardiotoxicity of Cancer Immunotherapy. Trends in Immunology, 2017, 38, 77-78.	6.8	32
107	Responses to reductive stress in the cardiovascular system. Free Radical Biology and Medicine, 2017, 109, 114-124.	2.9	107
108	The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics. Journal of the American College of Cardiology, 2017, 70, 2393-2410.	2.8	124

#	Article	IF	Citations
109	Categorizing biomedical research: the basics of translation. FASEB Journal, 2017, 31, 3210-3215.	0.5	9
110	NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges. Nature Reviews Drug Discovery, 2017, 16, 663-664.	46.4	2
111	An Unusual Cause of Leg Pain. New England Journal of Medicine, 2017, 377, 2267-2272.	27.0	0
112	Genetically encoded fluorescent sensors reveal dynamic regulation of NADPH metabolism. Nature Methods, 2017, 14, 720-728.	19.0	223
113	Putting the Patient Back Together â€" Social Medicine, Network Medicine, and the Limits of Reductionism. New England Journal of Medicine, 2017, 377, 2493-2499.	27.0	132
114	Is Oxygen Therapy Beneficial in Acute Myocardial Infarction? Simple Question, Complicated Mechanism, Simple Answer. New England Journal of Medicine, 2017, 377, 1286-1287.	27.0	17
115	Network analysis of the genomic basis of the placebo effect. JCI Insight, 2017, 2, .	5.0	37
116	Network Medicine. , 2017, , .		55
117	Incorporation of heparin-binding proteins into preformed dextran sulfate-chitosan nanoparticles. International Journal of Nanomedicine, 2016, Volume 11, 6149-6159.	6.7	13
118	Comparison of Protein N-Homocysteinylation in Rat Plasma under Elevated Homocysteine Using a Specific Chemical Labeling Method. Molecules, 2016, 21, 1195.	3.8	5
119	Systems Pharmacology and Rational Polypharmacy: Nitric Oxideâ^'Cyclic GMP Signaling Pathway as an Illustrative Example and Derivation of the General Case. PLoS Computational Biology, 2016, 12, e1004822.	3.2	23
120	In vivo monitoring of cellular energy metabolism using SoNar, a highly responsive sensor for NAD+/NADH redox state. Nature Protocols, 2016, 11, 1345-1359.	12.0	119
121	The Future of Medical Journal Publishing. Circulation, 2016, 133, 1621-1624.	1.6	5
122	Eye of the Beholder. New England Journal of Medicine, 2016, 374, 1774-1779.	27.0	5
123	Caveolin 1 Modulates Aldosteroneâ€Mediated Pathways of Glucose and Lipid Homeostasis. Journal of the American Heart Association, 2016, 5, .	3.7	41
124	Adaptions to Hypoxia and Redox Stress. Circulation Research, 2016, 119, 511-513.	4.5	23
125	Tip of the Tongue. New England Journal of Medicine, 2016, 375, 880-886.	27.0	3
126	Genetic Misdiagnoses and the Potential for Health Disparities. New England Journal of Medicine, 2016, 375, 655-665.	27.0	602

#	Article	IF	Citations
127	Randomized Controlled Trial of Social Media: Effect of Increased Intensity of the Intervention. Journal of the American Heart Association, 2016, 5, .	3.7	52
128	Selenoprotein Gene Nomenclature. Journal of Biological Chemistry, 2016, 291, 24036-24040.	3.4	207
129	Tissue Specificity of Human Disease Module. Scientific Reports, 2016, 6, 35241.	3.3	99
130	Endophenotype Network Models: Common Core of Complex Diseases. Scientific Reports, 2016, 6, 27414.	3.3	72
131	The Future of Cardiovascular Therapeutics. Circulation, 2016, 133, 2610-2617.	1.6	22
132	Precision medicine in cardiology. Nature Reviews Cardiology, 2016, 13, 591-602.	13.7	183
133	Upâ€regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension. FASEB Journal, 2016, 30, 2511-2527.	0.5	39
134	Illuminating drug action by network integration of disease genes: a case study of myocardial infarction. Molecular BioSystems, 2016, 12, 1653-1666.	2.9	21
135	Early pregnancy vitamin D status and risk of preeclampsia. Journal of Clinical Investigation, 2016, 126, 4702-4715.	8.2	160
136	Uncovering disease-disease relationships through the incomplete interactome. Science, 2015, 347, 1257601.	12.6	1,219
137	Hypoxia-Mediated Increases in l -2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress. Cell Metabolism, 2015, 22, 291-303.	16.2	270
138	A Randomized Trial of Social Media From Circulation. Circulation, 2015, 131, 28-33.	1.6	122
139	Nitroglycerin and Nitric Oxide â€" A Rondo of Themes in Cardiovascular Therapeutics. New England Journal of Medicine, 2015, 373, 277-280.	27.0	32
140	American Heart Association Cardiovascular Genome-Phenome Study. Circulation, 2015, 131, 100-112.	1.6	26
141	Maintenance of certification: Good intentions gone awry. Trends in Cardiovascular Medicine, 2015, 25, 312-314.	4.9	3
142	SoNar, a Highly Responsive NAD+/NADH Sensor, Allows High-Throughput Metabolic Screening of Anti-tumor Agents. Cell Metabolism, 2015, 21, 777-789.	16.2	311
143	Genetics and the placebo effect: the placebome. Trends in Molecular Medicine, 2015, 21, 285-294.	6.7	194
144	Incorporation of SDFâ€1Î± into Preâ€formed Dextran Sulfate and Chitosan Nanoparticles. FASEB Journal, 2015, 29, LB645.	0.5	0

#	Article	IF	Citations
145	A Celebration of Failure. Circulation, 2014, 129, 953-955.	1.6	12
146	Network-based association of hypoxia-responsive genes with cardiovascular diseases. New Journal of Physics, 2014, 16, 105014.	2.9	14
147	Upregulation of Steroidogenic Acute Regulatory Protein by Hypoxia Stimulates Aldosterone Synthesis in Pulmonary Artery Endothelial Cells to Promote Pulmonary Vascular Fibrosis. Circulation, 2014, 130, 168-179.	1.6	53
148	Epigenetic Modifications: Basic Mechanisms and Role in Cardiovascular Disease (2013 Grover) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622	1.7	122
149	Real-Time Assessment of the Metabolic Profile of Living Cells with Genetically Encoded NADH Sensors. Methods in Enzymology, 2014, 542, 349-367.	1.0	13
150	Redox Dysregulation in Vascular Pathobiology. Free Radical Biology and Medicine, 2014, 75, S2.	2.9	5
151	Analyzing networks of phenotypes in complex diseases: methodology and applications in COPD. BMC Systems Biology, 2014, 8, 78.	3.0	31
152	Plasma Levels of the Proinflammatory Chitinâ€Binding Glycoprotein YKLâ€40, Variation in the Chitinase 3â€Like 1 Gene (CHI3L1), and Incident Cardiovascular Events. Journal of the American Heart Association, 2014, 3, e000897.	3.7	44
153	Keshan Disease, Selenium Deficiency, and the Selenoproteome. New England Journal of Medicine, 2014, 370, 1756-1760.	27.0	193
154	Polymorphisms in Catechol- O -Methyltransferase Modify Treatment Effects of Aspirin on Risk of Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2160-2167.	2.4	35
155	Complexity and network dynamics in physiological adaptation: An integrated view. Physiology and Behavior, 2014, 131, 49-56.	2.1	28
156	Quantitative imaging of selenoprotein with multiâ€isotope imaging mass spectrometry (MIMS). Surface and Interface Analysis, 2014, 46, 154-157.	1.8	6
157	Tumor necrosis factor-Î±-mediated suppression of dual-specificity phosphatase 4: crosstalk between NFÎºB and MAPK regulates endothelial cell survival. Molecular and Cellular Biochemistry, 2013, 382, 153-162.	3.1	14
158	Venous Thrombosis in the Nephrotic Syndrome. New England Journal of Medicine, 2013, 368, 956-958.	27.0	93
159	S-Nitrosothiols and theS-Nitrosoproteome of the Cardiovascular System. Antioxidants and Redox Signaling, 2013, 18, 270-287.	5.4	79
160	The Identification of Nitric Oxide as Endothelium-Derived Relaxing Factor. Circulation Research, 2013, 113, 100-103.	4.5	70
161	Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. European Journal of Heart Failure, 2013, 15, 277-283.	7.1	91
162	Selenistasis: Epistatic Effects of Selenium on Cardiovascular Phenotype. Nutrients, 2013, 5, 340-358.	4.1	52

#	Article	IF	Citations
163	Raptor activation by aldosterone promotes apoptosis resistance in pulmonary artery smooth muscle cells to modulate adverse pulmonary vascular remodeling in pulmonary arterial hypertension. FASEB Journal, 2013, 27, 1199.1.	0.5	1
164	Aldosterone Activates Autophagy To Increase Fibroblast Collagen Synthesis and Vascular Stiffness. FASEB Journal, 2013, 27, 1188.9.	0.5	0
165	SDFâ€1 alpha Nanoglycan Complexes Exhibit Exended Retention Time and Beneficial Effect in Pulmonary Hypertension. FASEB Journal, 2013, 27, 1217.34.	0.5	0
166	Aldosterone Inactivates the Endothelin-B Receptor via a Cysteinyl Thiol Redox Switch to Decrease Pulmonary Endothelial Nitric Oxide Levels and Modulate Pulmonary Arterial Hypertension. Circulation, 2012, 126, 963-974.	1.6	171
167	Personalized Cardiovascular Medicine and Drug Development. Circulation, 2012, 125, 638-645.	1.6	41
168	Deciphering the molecular basis of human cardiovascular disease through network biology. Current Opinion in Cardiology, 2012, 27, 202-209.	1.8	30
169	MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary Hypertension. Circulation, 2012, 125, 1520-1532.	1.6	246
170	From Clinical Observation to Mechanism â€" Heyde's Syndrome. New England Journal of Medicine, 2012, 367, 1954-1956.	27.0	146
171	Network medicine approaches to the genetics of complex diseases. Discovery Medicine, 2012, 14, 143-52.	0.5	75
172	Both Maximal Expression of Selenoproteins and Selenoprotein Deficiency Can Promote Development of Type 2 Diabetes-Like Phenotype in Mice. Antioxidants and Redox Signaling, 2011, 14, 2327-2336.	5.4	158
173	Glutathione Peroxidase-1 in Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities. Antioxidants and Redox Signaling, 2011, 15, 1957-1997.	5.4	864
174	Systems Biology and Personalized Medicine: A Network Approach to Human Disease. Proceedings of the American Thoracic Society, 2011, 8, 196-198.	3.5	28
175	Network medicine: a network-based approach to human disease. Nature Reviews Genetics, 2011, 12, 56-68.	16.3	3,987
176	Systems biology and the future of medicine. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2011, 3, 619-627.	6.6	239
177	Lipid Metabolism by Gut Microbes and Atherosclerosis. Circulation Research, 2011, 109, 127-129.	4.5	45
178	Can Scientific Quality Be Quantified?. Circulation, 2011, 123, 947-950.	1.6	18
179	Glutathione Peroxidase-1 Deficiency Augments Proinflammatory Cytokine-induced Redox Signaling and Human Endothelial Cell Activation. Journal of Biological Chemistry, 2011, 286, 35407-35417.	3.4	67
180	Antioxidant enzyme deficiencies and vascular disease. Expert Review of Endocrinology and Metabolism, 2010, 5, 15-18.	2.4	4

#	Article	IF	Citations
181	The cellular response to hypoxia: tuning the system with microRNAs. Journal of Clinical Investigation, 2010, 120, 3815-3817.	8.2	86
182	Aldosterone Increases Oxidant Stress to Impair Guanylyl Cyclase Activity by Cysteinyl Thiol Oxidation in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2009, 284, 7665-7672.	3.4	89
183	Glutathione Peroxidase-1 Regulates Mitochondrial Function to Modulate Redox-dependent Cellular Responses. Journal of Biological Chemistry, 2009, 284, 11913-11921.	3.4	151
184	Oxidative risk for atherothrombotic cardiovascular disease. Free Radical Biology and Medicine, 2009, 47, 1673-1706.	2.9	178
185	The Treatment of Hyperhomocysteinemia. Annual Review of Medicine, 2009, 60, 39-54.	12.2	241
186	MicroRNA-210 Controls Mitochondrial Metabolism during Hypoxia by Repressing the Iron-Sulfur Cluster Assembly Proteins ISCU1/2. Cell Metabolism, 2009, 10, 273-284.	16.2	588
187	Response to the Letter by Grond-Ginsbach et al. Stroke, 2009, 40, .	2.0	0
188	Homocysteine-mediated thrombosis and angiostasis in vascular pathobiology. Journal of Clinical Investigation, 2009, 119, 3203-5.	8.2	27
189	DETERMINANTS OF THE ACTIVITY OF THE MAMMALIAN ANTIOXIDANT SELENOPROTEIN PLASMA GLUTATHIONE PEROXIDASE (GPxâ€3). FASEB Journal, 2009, 23, 500.1.	0.5	0
190	Pathogenic mechanisms of pulmonary arterial hypertension. Journal of Molecular and Cellular Cardiology, 2008, 44, 14-30.	1.9	229
191	Membrane Redox State and Apoptosis: Death by Peroxide. Cell Metabolism, 2008, 8, 182-183.	16.2	58
192	A Bold, New Initiative for Circulation. Circulation, 2008, 117, 4-5.	1.6	22
193	Aldosterone increases oxidant stress to inhibit soluble Guanylyl Cyclase activity in vascular smooth muscle cells. FASEB Journal, 2008, 22, 758.26.	0.5	0
194	Function and Regulation of Plasma Glutathione Peroxidase. FASEB Journal, 2008, 22, 998.2.	0.5	0
195	Human disease classification in the postgenomic era: A complex systems approach to human pathobiology. Molecular Systems Biology, 2007, 3, 124.	7.2	489
196	S-nitrosated proteins: formation, metabolism, and function. , 2007, , 201-221.		2
197	Regulation of the protein disulfide proteome by mitochondria in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 10813-10817.	7.1	118
198	Response to Letter by Grond-Ginsbach et al. Stroke, 2007, 38, .	2.0	0

#	Article	IF	Citations
199	Human Î±B-Crystallin Mutation Causes Oxido-Reductive Stress and Protein Aggregation Cardiomyopathy in Mice. Cell, 2007, 130, 427-439.	28.9	386
200	Overexpression and Purification of the Antioxidant Selenoprotein Plasma Glutathione Peroxidase. FASEB Journal, 2007, 21, A649.	0.5	0
201	Vascular Calcification. Circulation Research, 2006, 99, 1044-1059.	4.5	847
202	The NIH Budget and the Future of Biomedical Research. New England Journal of Medicine, 2006, 354, 1665-1667.	27.0	58
203	Nitric Oxide and Posttranslational Modification of the Vascular Proteome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1207-1214.	2.4	65
204	ATVB In Focus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 696-696.	2.4	0
205	Impaired Angiogenesis in Glutathione Peroxidase-1â€“Deficient Mice Is Associated With Endothelial Progenitor Cell Dysfunction. Circulation Research, 2006, 98, 254-261.	4.5	147
206	Nitric Oxide Donors in Cardiovascular Disease. , 2005, , 283-298.		0
207	Genetic Determinants of Vascular Oxidant Stress and Endothelial Dysfunction. Congestive Heart Failure, 2005, 11, 73-79.	2.0	7
208	Elevated Levels of Homocysteine Compromise Blood-Brain Barrier Integrity in Mice.. Blood, 2005, 106, 3856-3856.	1.4	0
209	Introduction to the Symposium Proceedings. Journal of Nutrition, 2004, 134, 2742S.	2.9	0
210	Session V: Therapeutic Strategies and Supplementationâ€” Discussion Summary. Journal of Nutrition, 2004, 134, 2895S.	2.9	0
211	L-Arginine and Atherothrombosis. Journal of Nutrition, 2004, 134, 2798S-2800S.	2.9	44
212	Ozone â€” From Environmental Pollutant to Atherogenic Determinant. New England Journal of Medicine, 2004, 350, 834-835.	27.0	20
213	Increased Myocardial Dysfunction After Ischemia-Reperfusion in Mice Lacking Glucose-6-Phosphate Dehydrogenase. Circulation, 2004, 109, 898-903.	1.6	118
214	Stem cells and regeneration of the cardiovascular system: facts, fictions, and uncertainties. Blood Cells, Molecules, and Diseases, 2004, 32, 97-99.	1.4	6
215	Exploring the Role of BMPR2 as Key Genetic Marker in Pulmonary Vascular Disease. Advances in Pulmonary Hypertension, 2004, 3, 4-5.	0.1	0
216	Homocysteine and atherothrombosis: Diagnosis and treatment. Current Atherosclerosis Reports, 2003, 5, 276-283.	4.8	23

#	Article	IF	Citations
217	Functional polymorphisms in a candidate gene for atherothrombosis. Journal of the American College of Cardiology, 2003, 41, 946-948.	2.8	14
218	Proteomics in Cardiovascular Biology and Medicine. Circulation, 2003, 108, 380-383.	1.6	42
219	Adverse Effects of Supplemental <scp>l</scp> -Arginine in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 3-5.	2.4	56
220	Glucose-6-Phosphate Dehydrogenase Overexpression Decreases Endothelial Cell Oxidant Stress and Increases Bioavailable Nitric Oxide. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 411-417.	2.4	179
221	Cellular Redox State and Endothelial Dysfunction in Mildly Hyperhomocysteinemic Cystathionine Î²-Synthaseâ€“Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 34-41.	2.4	147
222	Platelets and Cardiovascular Disease. European Journal of Cardiovascular Nursing, 2002, 1, 273-288.	0.9	116
223	Expression of 5-lipoxygenase in pulmonary artery endothelial cells. Biochemical Journal, 2002, 361, 267-276.	3.7	45
224	Oxidative stress in endothelial cell dysfunction and thrombosis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 359-360.	0.3	46
225	Nitric Oxide Donors and Cardiovascular Agents Modulating the Bioactivity of Nitric Oxide. Circulation Research, 2002, 90, 21-28.	4.5	436
226	Vascular control of platelet function. , 2002, , 432-456.		8
227	Nitric Oxide Insufficiency, Platelet Activation, and Arterial Thrombosis. Circulation Research, 2001, 88, 756-762.	4.5	542
228	Vessel wall-derived substances affecting platelets. , 2001, , 92-105.		1
229	The Tangled Web of Heart Failure: A Complex Network of Surrogates and Correlates. Journal of Cardiovascular Electrophysiology, 2001, 12, 301-302.	1.7	3
230	Effects of Race and Hypertension on Flow-Mediated and Nitroglycerin-Mediated Dilation of the Brachial Artery. Hypertension, 2001, 38, 1349-1354.	2.7	105
231	Glucoseâ€6â€phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailability. FASEB Journal, 2001, 15, 1771-1773.	0.5	136
232	What We Know and Donâ€™t Know About <scp>l</scp> -Arginine and NO. Circulation, 2000, 101, 2126-2129.	1.6	72
233	Endothelium, Nitric Oxide, and Atherosclerosis: From Basic Mechanisms to Clinical Implications. Circulation, 2000, 102, .	1.6	3
234	Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. Journal of Clinical Investigation, 2000, 106, 483-491.	8.2	353

#	Article	IF	Citations
235	Endothelial cell nitric oxide production in acute chest syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H1579-H1592.	3.2	28
236	Nitric Oxide Inhibits Thrombin Receptor-activating Peptide-induced Phosphoinositide 3-Kinase Activity in Human Platelets. Journal of Biological Chemistry, 1999, 274, 14368-14375.	3.4	80
237	Deficient Platelet-Derived Nitric Oxide and Enhanced Hemostasis in Mice Lacking the NOSIII Gene. Circulation Research, 1999, 84, 1416-1421.	4.5	195
238	Plasma Glutathione Peroxidase Deficiency and Platelet Insensitivity to Nitric Oxide in Children With Familial Stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2017-2023.	2.4	80
239	Oxidant stress in the vasculature. Current Atherosclerosis Reports, 1999, 1, 156-164.	4.8	102
240	Detection of Nitrosated Proteins. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 1999, 00, Unit 10.3.	1.1	1
241	Impaired Platelet Production of Nitric Oxide Predicts Presence of Acute Coronary Syndromes. Circulation, 1998, 98, 1481-1486.	1.6	168
242	Homocysteine, Oxidative Stress, and Vascular Disease. Hospital Practice (1995), 1997, 32, 81-92.	1.0	102
243	Endothelial Dysfunction and Atherothrombotic Occlusive Disease. Drugs, 1997, 54, 41-50.	10.9	12
244	Changes in the Amplitude of Cyclic Load Biphasically Modulate Endothelial Cell DNA Synthesis and Division. Vascular Medicine, 1997, 2, 19-24.	1.5	13
245	Hyperhomocyst(e)inemia and Atherothrombosis. Annals of the New York Academy of Sciences, 1997, 811, 48-59.	3.8	90
246	The Narrow Therapeutic Index of Thrombin Inhibition: Implications for Newer Antithrombotic Therapies. , 1997, 4, 315-316.		0
247	The Vascular Biology of S-Nitrosothiols, Nitrosated Derivatives of Thiols. Vascular Medicine, 1996, 1, 25-33.	1.5	12
248	Homocysteine, EDRF and Endothelial function. Journal of Nutrition, 1996, 126, 1290S-1294S.	2.9	60
249	Thrombin Inhibitors in Fibrinolysis. Circulation, 1996, 94, 863-865.	1.6	13
250	Restenosis following coronary angioplasty: Clinical presentations and therapeutic options. Clinical Cardiology, 1995, 18, 693-703.	1.8	57
251	Platelets and Plasminogen Activation. Thrombosis and Haemostasis, 1995, 74, 291-293.	3.4	21
252	A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature, 1993, 364, 626-632.	27.8	2,443

#	Article	IF	Citations
253	The induction of cellular interactions in atherogenesis and their modulation. Biochemical Society Transactions, 1993, 21, 656-659.	3.4	4
254	Antiplatelet and antithrombotic effects of organic nitrates. American Journal of Cardiology, 1992, 70, B18-B22.	1.6	105
255	Thrombolysis in the Management of Acute Myocardial Infarction and Unstable Angina Pectoris. Drugs, 1989, 37, 191-204.	10.9	6
256	Tissue plasminogen activator and acute pulmonary embolism. Journal of Cellular Biochemistry, 1988, 38, 303-312.	2.6	5
257	Structure of pre-pro-von Willebrand factor and its expression in heterologous cells. Nature, 1986, 324, 270-273.	27.8	212
258	Target Identification Among Known Drugs by Deep Learning from Heterogeneous Networks. SSRN Electronic Journal, 0, , .	0.4	3